Search for other papers by Bernardo Maia in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Endocrinology Division – Hospital Federal de Bonsucesso, Rio de Janeiro Brazil
Search for other papers by Leandro Kasuki in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Neuropatology and Molecular Genetics Laboratory – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
Introduction Acromegaly is a chronic systemic rare disease most commonly caused by a somatotroph pituitary adenoma with autonomous overproduction of growth hormone (GH) and a consequent increase in insulin-like growth factor type I (IGF
Search for other papers by A V Dreval in
Google Scholar
PubMed
Search for other papers by I V Trigolosova in
Google Scholar
PubMed
Search for other papers by I V Misnikova in
Google Scholar
PubMed
Search for other papers by Y A Kovalyova in
Google Scholar
PubMed
Search for other papers by R S Tishenina in
Google Scholar
PubMed
Search for other papers by I A Barsukov in
Google Scholar
PubMed
Search for other papers by A V Vinogradova in
Google Scholar
PubMed
Search for other papers by B H R Wolffenbuttel in
Google Scholar
PubMed
Introduction Disturbances of glucose metabolism are frequently observed in patients with acromegaly. In one of the first papers to be published on this topic, abnormal glucose tolerance was found in over 60% of patients with acromegaly (1) . The
Search for other papers by Antonella Giampietro in
Google Scholar
PubMed
Search for other papers by Sabrina Chiloiro in
Google Scholar
PubMed
Search for other papers by Claudio Urbani in
Google Scholar
PubMed
Search for other papers by Rosario Pivonello in
Google Scholar
PubMed
Search for other papers by Martin Ove Carlsson in
Google Scholar
PubMed
Search for other papers by Francesca Dassie in
Google Scholar
PubMed
Search for other papers by Nunzia Prencipe in
Google Scholar
PubMed
Search for other papers by Marta Ragonese in
Google Scholar
PubMed
Search for other papers by Roy Gomez in
Google Scholar
PubMed
Search for other papers by Simona Granato in
Google Scholar
PubMed
Search for other papers by Salvatore Cannavò in
Google Scholar
PubMed
Search for other papers by Silvia Grottoli in
Google Scholar
PubMed
Search for other papers by Pietro Maffei in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by Fausto Bogazzi in
Google Scholar
PubMed
Search for other papers by Antonio Bianchi in
Google Scholar
PubMed
Introduction Acromegaly is a chronic, slowly progressive disease characterized by somatic disfigurement, particularly of the extremities, and systemic manifestations ( 1 ). In most cases, acromegaly occurs as a consequence of a growth hormone
Cardiff University School of Medicine, Cardiff, UK
Search for other papers by Hei Yi Vivian Pak in
Google Scholar
PubMed
Search for other papers by Andrew Lansdown in
Google Scholar
PubMed
Centre for Diabetes and Endocrinology, University Hospital of Wales, Cardiff, UK
Search for other papers by Peter Taylor in
Google Scholar
PubMed
Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK
Search for other papers by Dafydd Aled Rees in
Google Scholar
PubMed
Search for other papers by John Stephen Davies in
Google Scholar
PubMed
Cardiff University School of Medicine, Cardiff, UK
Search for other papers by Caroline Hayhurst in
Google Scholar
PubMed
Introduction Acromegaly, usually due to a benign pituitary adenoma, is a rare condition that has profound effects on all aspects of the body ( 1 ). Besides causing soft-tissue growth, excess growth hormone is associated with co
Search for other papers by T L C Wolters in
Google Scholar
PubMed
Division of Vascular Medicine, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by C D C C van der Heijden in
Google Scholar
PubMed
Search for other papers by N van Leeuwen in
Google Scholar
PubMed
Search for other papers by B T P Hijmans-Kersten in
Google Scholar
PubMed
Search for other papers by M G Netea in
Google Scholar
PubMed
Search for other papers by J W A Smit in
Google Scholar
PubMed
Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK
Search for other papers by D H J Thijssen in
Google Scholar
PubMed
Search for other papers by A R M M Hermus in
Google Scholar
PubMed
Search for other papers by N P Riksen in
Google Scholar
PubMed
Search for other papers by R T Netea-Maier in
Google Scholar
PubMed
Introduction Acromegaly is caused by overproduction of growth hormone (GH), in most cases by a pituitary adenoma. GH in turn induces production of insulin-like growth factor 1 (IGF1) ( 1 ). Both GH and IGF1 have numerous metabolic and trophic
Search for other papers by Cecilia Follin in
Google Scholar
PubMed
Search for other papers by Sven Karlsson in
Google Scholar
PubMed
Introduction Acromegaly is a rare chronic condition caused by excess growth hormone (GH) secretion – usually from a pituitary tumour – and it has an incidence rate of only 3.3 cases per million people. The mean age at diagnosis is 40 years
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
Search for other papers by Feng Gu in
Google Scholar
PubMed
Search for other papers by Marcello D Bronstein in
Google Scholar
PubMed
Search for other papers by Thierry C Brue in
Google Scholar
PubMed
Search for other papers by Maria Fleseriu in
Google Scholar
PubMed
Search for other papers by Ilan Shimon in
Google Scholar
PubMed
Search for other papers by Aart J van der Lely in
Google Scholar
PubMed
Search for other papers by Shoba Ravichandran in
Google Scholar
PubMed
Search for other papers by Albert Kandra in
Google Scholar
PubMed
Search for other papers by Alberto M Pedroncelli in
Google Scholar
PubMed
Search for other papers by Annamaria A L Colao in
Google Scholar
PubMed
Introduction Acromegaly is a chronic endocrine disorder typically caused by a benign tumor of the pituitary gland ( 1 ), which hypersecretes growth hormone (GH) with subsequent secretion of insulin-like growth factor I (IGF-I). Long
Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Search for other papers by Bhuvanesh Mahendran in
Google Scholar
PubMed
Search for other papers by K Shrinivas Reddy in
Google Scholar
PubMed
Search for other papers by Jasmina Ahluwalia in
Google Scholar
PubMed
Search for other papers by Kim Vaiphei in
Google Scholar
PubMed
Search for other papers by Rakesh K Kochhar in
Google Scholar
PubMed
Search for other papers by Prakamya Gupta in
Google Scholar
PubMed
Search for other papers by Anand Srinivasan in
Google Scholar
PubMed
Search for other papers by Mahesh Prakash in
Google Scholar
PubMed
Search for other papers by Kanchan Kumar Mukherjee in
Google Scholar
PubMed
Search for other papers by Viral N Shah in
Google Scholar
PubMed
Search for other papers by Girish Parthan in
Google Scholar
PubMed
Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Introduction Acromegaly is most commonly caused by a growth hormone (GH)-producing pituitary tumor and is potentially life-threatening if untreated. Early diagnosis and treatment of acromegaly result in increased longevity and better quality of life
Search for other papers by A J Varewijck in
Google Scholar
PubMed
Search for other papers by A J van der Lely in
Google Scholar
PubMed
Search for other papers by S J C M M Neggers in
Google Scholar
PubMed
Search for other papers by S W J Lamberts in
Google Scholar
PubMed
Search for other papers by L J Hofland in
Google Scholar
PubMed
Search for other papers by J A M J L Janssen in
Google Scholar
PubMed
Introduction Acromegaly is characterized by excess secretion of growth hormone (GH) causing multisystem-associated morbidities and increased mortality. GH is considered as the main regulator of circulating total insulin-like growth factor 1 (IGF1
Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Search for other papers by Peter Wolf in
Google Scholar
PubMed
Search for other papers by Alexandre Dormoy in
Google Scholar
PubMed
Search for other papers by Luigi Maione in
Google Scholar
PubMed
Search for other papers by Sylvie Salenave in
Google Scholar
PubMed
Search for other papers by Jacques Young in
Google Scholar
PubMed
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Introduction Acromegaly results in a clinical syndrome following increased serum concentrations of growth hormone (GH) and insulin-like growth factor-1 (IGF-1). If not adequately treated, GH excess is associated with increased morbidity and